COSRX · Reverse dupe

What is the Centella Blemish Cream a dupe for?

Treatment4 matches
Quick answer: the COSRX Centella Blemish Cream is a budget stand-in for the La Roche-Posay Effaclar Duo+ — 70% active overlap sharing Niacinamide. It also overlaps with 3 other picks below.

Pricier picks the Centella Blemish Cream matches

La Roche-Posay
70%
Active overlap
Pricier pickNiacinamide
Why it holds up: shares the same hero active — Niacinamide — which is what drives results here.
Full ingredient analysis →See them side by side →
66%
Active overlap
Pricier pickNiacinamide
Why it holds up: shares the same hero active — Niacinamide — which is what drives results here.
Full ingredient analysis →See them side by side →
66%
Active overlap
Pricier pickNiacinamide
Why it holds up: shares the same hero active — Niacinamide — which is what drives results here.
Full ingredient analysis →See them side by side →
50%
Active overlap
Pricier pickCentella AsiaticaNiacinamide
Why it holds up: shares the same hero actives — Centella Asiatica, Niacinamide — which is what drives results here.
Full ingredient analysis →See them side by side →

Every match above mirrors an existing dupe page verbatim — re-derived from the 4 comparisons where the Centella Blemish Cream appears as an alternative. No invented data.

Common questions

Is the COSRX Centella Blemish Cream a real dupe?
It overlaps on hero actives with 4 same-category products in our catalogue — most closely the La Roche-Posay Effaclar Duo+ at 70% active overlap. "Dupe" here means shared active ingredients, not an identical formula.
Does a higher overlap mean it is better?
No — overlap only measures shared hero actives. Base, supporting actives, texture and price still differ, so use the side-by-side compare for the full picture.
Go deeper
Centella Blemish Cream
Full ingredient breakdown for this product.
Open the analysis →
Browse
All dupes
Every dupe breakdown on the shelf.
Open the dupe hub →

Educational information only — not medical advice. Overlap reflects shared hero actives, not clinical equivalence.